119th Congress · introduced in the House · Feb 26, 2025
Finn Sawyer Access to Cancer Testing Act
Official title from Congress.gov
Latest action (Feb 26, 2025): Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Feb 26, 2025)
Finn Sawyer Access to Cancer Testing Act
This bill provides for coverage of certain cancer diagnostic and laboratory tests under Medicare, Medicaid, and the Children's Health Insurance Program (CHIP). Specifically, the bill provides for coverage of microarray analysis, DNA and RNA sequencing, whole-exome sequencing, and other next-generation sequencing for individuals diagnosed with cancer.
Additionally, the Department of Health and Human Services must establish an education and awareness program for physicians and the public about genomic testing and the role of genetic counselors.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Cancer · Health care costs and insurance · Health care coverage and access · Health promotion and preventive care · Medicaid · Medical tests and diagnostic methods · Medicare · Poverty and welfare assistance · State and local government operations
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
1 citation.
EXACT SCIENCES CORPORATION · lobbying firm or registrant: ALPINE GROUP PARTNERS, LLC.
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 17, 2025 · issue area: Health Issues
$60,000
Paid to lobbying firm
Issues related FDA regulation of laboratory tests H.R. 842, S.339 the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act H.R.1620, S.755 Finn Sawyer Access to Cancer Testing Act
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing